# Pharmacokinetics Safety and Acceptability of DRV/r for Children Living With HIV

> **NCT06139796** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **PENTA Foundation**

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** DRV/r FDC (120/20mg)

## Key facts

- **NCT ID:** NCT06139796
- **Lead sponsor:** PENTA Foundation
- **Sponsor class:** NETWORK
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-02-01
- **Primary completion:** 2025-07-09
- **Final completion:** 2025-07-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study not started as the IMP is re-worked by the manufacturer
- **Last updated:** 2026-03-05

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06139796

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06139796, "Pharmacokinetics Safety and Acceptability of DRV/r for Children Living With HIV". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06139796. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*